BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$284.60 USD
+42.65 (17.63%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $285.16 +0.56 (0.20%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIO 284.60 +42.65(17.63%)
Will BIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIO
Earnings Preview: Bio-Rad Laboratories (BIO) Q2 Earnings Expected to Decline
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms
BIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for July 10th
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends
Other News for BIO
Bio-Rad (BIO) Stock Surges Over 15%
UBS Increases Price Target for Bio-Rad (BIO) to $325
RBC Capital Raises Price Target for Bio-Rad Laboratories (BIO) to $409 | BIO Stock News
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
BIO Crosses Above Key Moving Average Level